Lemtrada
Lemtrada ingredients
| Active ingredient | Strength |
|---|---|
| Alemtuzumab | 12 mg/1.2mL |
What Lemtrada is used for
The FDA lists the approved uses on the official label (below). In the EU, alemtuzumab is approved as Lemtrada for:
Lemtrada is indicated for adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Lemtrada
- Generic name
- Alemtuzumab
- Made by
- Genzyme Corporation
- Forms
- Injection, Solution, Concentrate
- Given
- Intravenous
- Drug class
- CD52-directed Cytolytic Antibody
- FDA approval
- Biologic licence (BLA) BLA103948
- On the US market since
- 2014
Official information
- Lemtrada prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Alemtuzumab)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Lemtrada?
Lemtrada (Alemtuzumab) is a cancer medicine made by Genzyme Corporation, approved by the US FDA.
What are the ingredients of Lemtrada?
Lemtrada contains Alemtuzumab (12 mg/1.2mL).
Is Lemtrada approved in Europe?
The same active substance is approved in the EU as Lemtrada.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA